Cantor Fitzgerald Reaffirms Overweight Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $7.00 price objective on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 329.45% from the stock’s previous close.

Several other research firms also recently issued reports on TSHA. Canaccord Genuity Group dropped their price objective on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a report on Tuesday. Finally, Chardan Capital reiterated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, August 13th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $6.38.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ:TSHA opened at $1.63 on Tuesday. The company has a market cap of $334.06 million, a P/E ratio of -8.15 and a beta of 0.44. The company has a debt-to-equity ratio of 0.35, a quick ratio of 5.22 and a current ratio of 5.22. Taysha Gene Therapies has a one year low of $1.19 and a one year high of $4.32. The business’s 50-day simple moving average is $1.97 and its 200 day simple moving average is $2.39.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. Taysha Gene Therapies had a negative return on equity of 168.91% and a negative net margin of 888.18%. The company had revenue of $1.11 million for the quarter, compared to the consensus estimate of $3.62 million. During the same period in the previous year, the business earned ($0.38) EPS. On average, sell-side analysts forecast that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Creative Planning acquired a new position in Taysha Gene Therapies during the 3rd quarter valued at approximately $28,000. Principal Financial Group Inc. acquired a new position in Taysha Gene Therapies during the 2nd quarter valued at approximately $48,000. China Universal Asset Management Co. Ltd. boosted its position in Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after purchasing an additional 17,446 shares during the period. Intech Investment Management LLC acquired a new position in Taysha Gene Therapies during the 3rd quarter valued at approximately $85,000. Finally, Scientech Research LLC acquired a new position in Taysha Gene Therapies during the 2nd quarter valued at approximately $97,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.